SI2887923T1 - Oftalmična formulacija polioksilnega lipida ali polioksilne maščobne kisline in zdravljenje očesnih stanj - Google Patents

Oftalmična formulacija polioksilnega lipida ali polioksilne maščobne kisline in zdravljenje očesnih stanj

Info

Publication number
SI2887923T1
SI2887923T1 SI201332048T SI201332048T SI2887923T1 SI 2887923 T1 SI2887923 T1 SI 2887923T1 SI 201332048 T SI201332048 T SI 201332048T SI 201332048 T SI201332048 T SI 201332048T SI 2887923 T1 SI2887923 T1 SI 2887923T1
Authority
SI
Slovenia
Prior art keywords
polyoxyl
treatment
fatty acid
ophthalmic formulation
ocular conditions
Prior art date
Application number
SI201332048T
Other languages
English (en)
Inventor
Ashim K. Mitra
Sidney L. Weiss
Eugene J. Mcnally
Original Assignee
Sun Pharmaceutical Industries Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50148510&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2887923(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sun Pharmaceutical Industries Limited filed Critical Sun Pharmaceutical Industries Limited
Publication of SI2887923T1 publication Critical patent/SI2887923T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI201332048T 2012-08-24 2013-08-23 Oftalmična formulacija polioksilnega lipida ali polioksilne maščobne kisline in zdravljenje očesnih stanj SI2887923T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261693189P 2012-08-24 2012-08-24
EP13831463.8A EP2887923B1 (en) 2012-08-24 2013-08-23 Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions
PCT/US2013/056513 WO2014032026A1 (en) 2012-08-24 2013-08-23 Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions

Publications (1)

Publication Number Publication Date
SI2887923T1 true SI2887923T1 (sl) 2023-09-29

Family

ID=50148510

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201332048T SI2887923T1 (sl) 2012-08-24 2013-08-23 Oftalmična formulacija polioksilnega lipida ali polioksilne maščobne kisline in zdravljenje očesnih stanj

Country Status (16)

Country Link
US (5) US8980839B2 (sl)
EP (2) EP4218729A1 (sl)
AU (1) AU2013305539B2 (sl)
CA (2) CA2914472C (sl)
DK (1) DK2887923T3 (sl)
ES (1) ES2948387T3 (sl)
FI (1) FI2887923T3 (sl)
HK (1) HK1211867A1 (sl)
HR (1) HRP20230559T1 (sl)
HU (1) HUE062145T2 (sl)
LT (1) LT2887923T (sl)
MX (1) MX361858B (sl)
PL (1) PL2887923T3 (sl)
PT (1) PT2887923T (sl)
SI (1) SI2887923T1 (sl)
WO (1) WO2014032026A1 (sl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE062145T2 (hu) 2012-08-24 2023-10-28 Sun Pharmaceutical Ind Ltd Polioxil lipid vagy polioxil zsírsav szemészeti készítménye és szemészeti állapotok kezelése
BR112016027379A2 (pt) * 2014-05-23 2018-06-26 Ocular Tech Sarl formulações tópicas e seus usos
WO2016172712A2 (en) 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
WO2016028800A1 (en) * 2014-08-20 2016-02-25 A.T. Resolve Sarl Treatment of corneal haze
US11382909B2 (en) 2014-09-05 2022-07-12 Sydnexis, Inc. Ophthalmic composition
KR101587412B1 (ko) * 2014-10-17 2016-01-21 주식회사 휴온스 사이클로스포린 및 트레할로스를 포함하는 안과용 조성물
US20180133217A1 (en) * 2015-05-04 2018-05-17 Ocular Technologies Sarl Topical formulations and uses thereof
CN107847432A (zh) * 2015-05-29 2018-03-27 西德奈克西斯公司 D2o稳定化的药物制剂
AU2016351588A1 (en) 2015-11-10 2018-05-24 Sun Pharma Global Fze Topical formulations and uses thereof
US20180333352A1 (en) * 2015-11-12 2018-11-22 Sun Pharma Global Fze Topical formulations and uses thereof
BR112018067946A8 (pt) 2016-02-29 2022-11-08 Sun Pharma Global Fze Formulações tópicas contendo ciclosporina e usos das mesmas
EP3448361A4 (en) 2016-04-29 2019-11-20 I-Novion, Inc. LIQUID PENTABLOCK COPOLYMER FORMULATIONS FOR CONTINUOUS RELEASE OF THERAPEUTICS
HRP20220046T1 (hr) * 2016-11-29 2022-04-15 Oculis SA Priprema čvrstih kompleksa ciklodekstrina za uporabu oftalmološki aktivnih farmaceutskih sastojka
CN107334734B (zh) * 2017-07-10 2020-03-17 浙江大学 一种西罗莫司或其衍生物的眼用制剂
WO2021001366A1 (en) 2019-07-01 2021-01-07 Oculis SA Method for stabilizing the ph of an aqueous composition comprising a drug
US20230093908A1 (en) * 2019-08-18 2023-03-30 IVIEW Therapeutics (Zhuhai) Co., Ltd. In-situ Gel Containing Cyclosporine Micelles as Sustained Ophthalmic Drug Delivery System
BR112022011276A2 (pt) * 2019-12-09 2022-09-06 Univ Louisiana State Biomolécula para tratamento de patologias da córnea
JP2024521968A (ja) 2021-06-14 2024-06-04 サン ファーマシューティカル インダストリーズ リミテッド 白内障手術を受ける患者において使用するための、シクロスポリン製剤
CN117957011A (zh) * 2021-08-20 2024-04-30 太阳制药工业有限公司 稳定的环孢素眼用制剂及其制造方法

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2406A (en) * 1841-12-30 Construction of railroad-scbapers fob cleaning te-ie tracks from sl
FR520E (fr) 1901-11-13 1903-01-26 Bermont Victor Etienne Procédé industriel d'extraction directe du zinc contenu dans les minerais oxydés, et plus spécialement dans la smithsonite (znco3) et la calamine (h2zn2sio5)
DK0642332T3 (da) * 1992-05-13 1997-06-16 Sandoz Ltd Ophthalmiske præparater indeholdende cyclosporin
NZ247516A (en) * 1993-04-28 1995-02-24 Bernard Charles Sherman Water dispersible pharmaceutical compositions comprising drug dissolved in solvent system comprising at least one alcohol and at least one surfactant
US5484597A (en) 1993-07-30 1996-01-16 Chesebrough-Pond's Usa Co. Clear hydroalcholic cosmetic microemulsions
NZ280689A (en) * 1995-12-15 1997-08-22 Bernard Charles Sherma Sherman Pharmaceutical composition comprising a cyclosporipharmaceutical composition comprising a cyclosporin; a tocol, tocopherol or tocotrienol; and propylen; a tocol, tocopherol or tocotrienol; and propylene carbonate or polyethylene glycol ne carbonate or polyethylene glycol
MX9701946A (es) 1997-03-14 1998-04-30 Arturo Jimenez Bayardo Solucion oftalmica transportadora.
US6816968B1 (en) * 1998-07-10 2004-11-09 Silverbrook Research Pty Ltd Consumable authentication protocol and system
US7678836B2 (en) 1999-11-04 2010-03-16 Fxs Ventures, Llc Method for rendering a contact lens wettable
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
EP1296923B3 (en) 2000-02-16 2012-04-11 The Brigham And Women's Hospital, Inc. Aspirin-triggered lipid mediators
US20030176356A1 (en) 2001-04-24 2003-09-18 University Of North Texas Health Science Center Endothelin antagonists and endothelin-converting enzyme inhibitors for the treatment of glaucoma
CA2461730C (en) 2001-10-19 2012-05-15 Isotechnika Inc. Novel cyclosporin analog microemulsion preconcentrates
WO2003053423A2 (en) 2001-12-18 2003-07-03 The Brigham And Women's Hospital Inhibition or prevention of infection by bacteria with epa, dha or analogs
ES2527753T3 (es) 2002-04-01 2015-01-29 University Of Southern California Eicosanoides trihidroxi poliinsaturados
US7582785B2 (en) 2002-04-01 2009-09-01 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
EP3584235A3 (en) 2002-08-12 2020-04-22 Brigham and Women's Hospital Resolvins: biotemplates for novel therapeutic interventions
US7759395B2 (en) 2002-08-12 2010-07-20 The Brigham And Women's Hospital, Inc. Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
US20040213782A1 (en) 2003-02-03 2004-10-28 Pharmacia Corporation Compositions of an aquaporin modulating agent and an aqueous humor modulating agent for the treatment of elevated intraocular pressure
JP2004238346A (ja) * 2003-02-07 2004-08-26 Shiono Chemical Co Ltd トラニラストの安定な水溶液製剤
WO2004078143A2 (en) 2003-03-05 2004-09-16 The Brigham And Women's Hospital Inc. Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs
WO2004096261A1 (es) 2003-05-02 2004-11-11 Arturo Jimenez Bayardo Metodo para preparar una solucion acuosa de ciclosporina-a y solucion acuosa resultante
US7087237B2 (en) * 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
WO2005105025A1 (en) 2004-04-14 2005-11-10 Boston University Methods and compositions for preventing or treating periodontal diseases
US20060020563A1 (en) * 2004-07-26 2006-01-26 Coleman Christopher R Supervised neural network for encoding continuous curves
ES2314354T3 (es) * 2004-11-09 2009-03-16 Novagali Pharma S.A. Emulsion de tipo aceite en agua con baja concentracion de agente cationico y potencial zeta positivo.
BRPI0516803A (pt) 2004-11-19 2008-09-23 Martek Biosciences Corp oxilipinas de ácidos graxos polinsaturados de cadeia longa e métodos de produção e uso dos mesmos
WO2006132342A1 (ja) * 2005-06-09 2006-12-14 Santen Pharmaceutical Co., Ltd. ロフルミラスト点眼液
JP5235662B2 (ja) * 2005-06-16 2013-07-10 ミリアド ジェネティクス， インコーポレイテッド 薬学的組成物およびその使用
US20070015691A1 (en) 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
PL1904056T3 (pl) 2005-07-18 2009-09-30 Minu Llc Zastosowanie makrolidu do przywracania czucia rogówkowego
EP1983977A4 (en) 2006-01-31 2011-11-30 Martek Biosciences Corp OXYLIPINES FROM STEARIDONIC ACID AND GAMMA-LINOLIC ACID AND METHOD FOR THE PRODUCTION AND USE THEREOF
US10137083B2 (en) * 2006-03-07 2018-11-27 SGN Nanopharma Inc Ophthalmic preparations
FR2904568B1 (fr) * 2006-08-03 2008-09-05 Dynastar Skis Sa Procede de fabrication d'une planche de glisse
WO2008103753A2 (en) 2007-02-20 2008-08-28 Martek Biosciences Corporation Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
US20100310462A1 (en) 2007-04-18 2010-12-09 Biochromix Ab Binding of pathological forms of proteins using conjugated polyelectrolytes
US8512687B2 (en) * 2007-07-09 2013-08-20 Novagali Pharma Sa Oil in water emulsion comprising NSAIDs and quaternary ammonium halides
US20090048929A1 (en) * 2007-08-15 2009-02-19 Paul Im Authenticated travel record
US9456980B2 (en) 2007-08-29 2016-10-04 Wakamoto Pharmaceutical Co., Ltd. Latanoprost-containing aqueous pharmaceutical composition
MX2007011165A (es) 2007-09-12 2009-03-11 Arturo Jimenez Bayardo Composición farmacéutica estable de timolol, dorzolamida y brimonidina.
CA3014633C (en) 2007-10-08 2022-05-17 Aurinia Pharmaceuticals Inc. Ophthalmic compositions comprising calcineurin inhibitors or mtor inhibitors
CA2710843A1 (en) * 2008-01-04 2009-07-16 Alcon Pharmaceuticals Ltd. Stable aqueous cyclosporin compositions
TWI544927B (zh) 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
CA2725523C (en) * 2008-05-28 2017-01-10 Alcon Research, Ltd. Self-preserved emulsions
EP2127638A1 (en) * 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
JP2012528857A (ja) * 2009-06-02 2012-11-15 ウー，ニエン 純粋ｐｅｇ−脂質コンジュゲート
JP2012529509A (ja) * 2009-06-09 2012-11-22 ラックス・バイオサイエンシーズ・インコーポレイテッド 眼科用用途のための局所薬物送達システム
RU2012115103A (ru) * 2009-09-17 2013-10-27 Сэндзю Фармасьютикал Ко., Лтд. Водные глазные капли, содержащие латанопрост, и способ ингибирования адсорбции латанопроста полимером
US8637569B2 (en) 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
WO2011106697A1 (en) 2010-02-25 2011-09-01 Schepens Eye Research Institute Therapeutic compositions for the treatment of dry eye disease
CA2798923A1 (en) 2010-05-07 2011-11-10 Sun Pharma Advanced Research Company Ltd. Novel ophthalmic compositions
WO2013025696A1 (en) 2011-08-15 2013-02-21 Teva Pharmaceutical Industries Ltd. Ophthalmic formulations and processes for their preparation
KR101211902B1 (ko) 2012-04-30 2012-12-13 주식회사 휴온스 사이클로스포린 함유 무자극성 나노에멀젼 안약 조성물
IN2014MN02236A (sl) 2012-05-11 2015-07-24 Cipla Ltd
HUE062145T2 (hu) 2012-08-24 2023-10-28 Sun Pharmaceutical Ind Ltd Polioxil lipid vagy polioxil zsírsav szemészeti készítménye és szemészeti állapotok kezelése
US10946076B2 (en) 2013-02-13 2021-03-16 The Research Foundation For The State University Of New York Glaucoma treatment
BR112016027379A2 (pt) 2014-05-23 2018-06-26 Ocular Tech Sarl formulações tópicas e seus usos
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
US20180133217A1 (en) 2015-05-04 2018-05-17 Ocular Technologies Sarl Topical formulations and uses thereof
AU2016351588A1 (en) 2015-11-10 2018-05-24 Sun Pharma Global Fze Topical formulations and uses thereof
US20180333352A1 (en) 2015-11-12 2018-11-22 Sun Pharma Global Fze Topical formulations and uses thereof
BR112018067946A8 (pt) 2016-02-29 2022-11-08 Sun Pharma Global Fze Formulações tópicas contendo ciclosporina e usos das mesmas
WO2017152129A2 (en) 2016-03-03 2017-09-08 Ocular Technologies Sarl Treatment of glaucoma and/or retinal diseases and formulations useful therefore

Also Published As

Publication number Publication date
AU2013305539B2 (en) 2018-08-02
US9937225B2 (en) 2018-04-10
EP2887923A1 (en) 2015-07-01
MX2015002239A (es) 2016-01-08
CA3050298A1 (en) 2014-02-27
ES2948387T3 (es) 2023-09-11
EP2887923A4 (en) 2016-03-30
LT2887923T (lt) 2023-07-10
AU2013305539A1 (en) 2015-03-12
HK1211867A1 (en) 2016-06-03
CA2914472A1 (en) 2014-02-27
MX361858B (es) 2018-12-18
US8980839B2 (en) 2015-03-17
PL2887923T3 (pl) 2023-08-14
WO2014032026A1 (en) 2014-02-27
HUE062145T2 (hu) 2023-10-28
US20160256520A1 (en) 2016-09-08
EP2887923B1 (en) 2023-04-05
US10441630B2 (en) 2019-10-15
US20150148299A1 (en) 2015-05-28
PT2887923T (pt) 2023-06-28
US20160256521A1 (en) 2016-09-08
CA2914472C (en) 2019-09-03
HRP20230559T1 (hr) 2023-09-15
US20150165048A1 (en) 2015-06-18
FI2887923T3 (fi) 2023-06-30
US20140057854A1 (en) 2014-02-27
DK2887923T3 (da) 2023-07-03
EP4218729A1 (en) 2023-08-02

Similar Documents

Publication Publication Date Title
HK1211867A1 (en) Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions
HK1213192A1 (zh) 用於在人類受試者中治療眼部疾病的方法和裝置
HK1198631A1 (en) Prevention and treatment of ocular conditions
HK1246646A1 (zh) 用於治療糖尿病性視網膜病及其他眼科疾病的方法
BR112012032948A2 (pt) dispositivos injectores e método de suprimento de solução oftálmica à córnea do olho
HK1205875A1 (en) Aqueous herbicide concentrates containing fatty acid alkyl esters, fatty acid amides, or triglyceride fatty acid esters and methods of use
IL236920B (en) Ophthalmic compositions and their use for treatment of eye diseases and disorders in animals
EP2819687A4 (en) COMPOSITIONS AND METHODS FOR TREATING PERIPHERAL VASCULAR DISEASE
IL230957A0 (en) Pharmacy methods and preparations for the treatment of an eye disease in a patient
IL235762A (en) A stable lotion to prevent skin irritation and items that use it
PL2814463T3 (pl) Okulistyczne kompozycje farmaceutyczne i sposoby ich wytwarzania i stosowania
EP2906295A4 (en) METHODS OF TREATING OCULAR DISEASES
EP2849749A4 (en) HISTATIN FOR HEALING CORNEAL WOUNDS AND EYE SURFACE DISEASES
IL235874A0 (en) Treatment of ocular inflammatory diseases by laquinimod
EP2838509A4 (en) FORMULATIONS AND METHOD FOR THE TREATMENT OF INFLAMMATORY SKIN DISEASES
IL239078A0 (en) Protein for use in the treatment of eye diseases
EP2844268A4 (en) METHOD FOR THE TREATMENT OF EYE DISEASE AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASE